Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam.
about
Beyond Susceptible and Resistant, Part II: Treatment of Infections Due to Gram-Negative Organisms Producing Extended-Spectrum β-LactamasesBacterial temporal dynamics enable optimal design of antibiotic treatmentMarkov Networks of Collateral Resistance: National Antimicrobial Resistance Monitoring System Surveillance Results from Escherichia coli Isolates, 2004-2012Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunologyAntimicrobial susceptibilities of Proteus mirabilis: a longitudinal nationwide study from the Taiwan surveillance of antimicrobial resistance (TSAR) programThe evolution of the regulatory framework for antibacterial agentsPharmacokinetic-pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with acute bacterial skin and skin structure infections.Clinical usefulness of the 2010 clinical and laboratory standards institute revised breakpoints for cephalosporin use in the treatment of bacteremia caused by Escherichia coli or Klebsiella spp.Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremiaAntimicrobial Non-Susceptibility of Escherichia coli from Outpatients and Patients Visiting Emergency Rooms in TaiwanPG1058 Is a Novel Multidomain Protein Component of the Bacterial Type IX Secretion SystemCefepime Therapy for Monomicrobial Enterobacter cloacae Bacteremia: Unfavorable Outcomes in Patients Infected by Cefepime-Susceptible Dose-Dependent Isolates.Carbapenem-Resistant Enterobacteriaceae Infections in Children.Determining a clinical framework for use of cefepime and β-lactam/β-lactamase inhibitors in the treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.Treatment of multidrug-resistant Gram-negative infections in children.β-lactam/β-lactamase inhibitor combinations: from then to now.Ecthyma gangrenosum and ecthyma-like lesions: review article.Evaluating outcomes of alternative dosing strategies for cefepime: a qualitative systematic review.Impact of appropriateness of empiric therapy on outcomes in community-onset bacteremia by extended-spectrum-β-lactamase producing Escherichia coli and Klebisella pneumoniae definitively treated with carbapenems.Recent Updates on the Role of Pharmacokinetics-pharmacodynamics in Antimicrobial Susceptibility Testing as Applied to Clinical Practice.Examining the Clinical Effectiveness of Non-Carbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae.A review of the pharmacokinetics and pharmacodynamics of aztreonam.Optimizing Guideline-Recommended Antibiotic Doses for Pediatric Infective Endocarditis.Updates in the Management of Cephalosporin-Resistant Gram-Negative Bacteria.Integrating forecast probabilities in antibiograms: a way to guide antimicrobial prescriptions more reliably?Impact of CLSI Breakpoint Changes on Microbiology Laboratories and Antimicrobial Stewardship ProgramsEvaluation of a Computerized Decision Support Intervention to Decrease Use of Anti-Pseudomonal Carbapenems in Penicillin Allergic Patients.Emerging Resistance, New Antimicrobial Agents … but No Tests! The Challenge of Antimicrobial Susceptibility Testing in the Current US Regulatory Landscape.Determining the optimal ceftriaxone MIC for triggering extended-spectrum β-lactamase confirmatory testing.WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases.Impact of Revised Broad-Spectrum Cephalosporin Clinical and Laboratory Standards Institute Breakpoints on Susceptibility in Enterobacteriaceae Producing AmpC β-Lactamase.WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide in 2015.Severe skull base osteomyelitis caused by Pseudomonas aeruginosa with successful outcome after prolonged outpatient therapy with continuous infusion of ceftazidime and oral ciprofloxacin: a case report.Prediction of in vivo and in vitro infection model results using a semimechanistic model of avibactam and aztreonam combination against multidrug resistant organisms.Antimicrobial Activity of High-Proportion Cefepime-Tazobactam (WCK 4282) against a Large Number of Gram-Negative Isolates Collected Worldwide in 2014.Potentiation of ceftazidime by avibactam against β-lactam-resistant Pseudomonas aeruginosa in an in vitro infection model.Defining Extended Spectrum β-Lactamases: Implications of Minimum Inhibitory Concentration-Based Screening Versus Clavulanate Confirmation Testing.Improved Accuracy of Cefepime Susceptibility Testing for Extended-Spectrum-Beta-Lactamase-Producing Enterobacteriaceae with an On-Demand Digital Dispensing Method.Evaluation of Aztreonam Dosing Regimens in Patients With Normal and Impaired Renal Function: A Population Pharmacokinetic Modeling and Monte Carlo Simulation Analysis.Clinical laboratory detection of carbapenem-resistant and carbapenemase-producing Enterobacteriaceae.
P2860
Q28249617-4F4F7241-ED1B-45E3-92A6-4A14C4226FF1Q28546654-818DFDF3-7D25-4AB8-82A3-88E1F4ED514FQ28553520-1DEC63E5-5BD1-4E92-976F-6F15A76D0815Q33827819-7009F34C-40EF-4904-8FCC-ECE5F885F3EEQ34174397-3D9984DE-1301-40AA-9367-26C7DA2162B4Q34693386-32BFC6E8-5AF4-4DC2-BCB0-4E808A39B477Q34922533-147895AA-1132-4AD8-BAC7-1742082B2FC5Q35156063-A0E39D80-5BD4-4B27-80A5-E6CBDFB4DF12Q35715650-8572B595-25E8-42A5-8C2F-3E4154358460Q35859801-B1072FE3-9FDA-4004-AC43-8D47D6759EF5Q36155466-782C939D-40A6-42E7-BA60-7DB3BEE6D52DQ36290474-C1BAA75B-19FB-49D4-B38A-14911BF96DE9Q37154718-44C81A25-8A08-40A2-8CA1-06E223C14426Q38165138-6314BC0D-9E8C-4EAB-B340-D66578C2296FQ38185648-093EF228-7075-4012-8863-CB9F23F15AC9Q38264182-A264DAE8-9C41-4F39-8B94-2FC7652DD8F5Q38269326-33BBF102-CAD4-4465-90BF-58C05FC9D1A6Q38313276-C7435499-4060-4157-A669-DC6E67713877Q38401630-FFADF741-CBAD-404D-B96C-4878093B2799Q38536299-5E8D78B6-E51D-4E43-AA4B-75A1E7D887D9Q38792841-6E349D1B-39BE-49DE-B1DD-0132B8A6004DQ38873850-D59EEF17-7989-4675-BCD1-FD85B81CA9F1Q38903089-591AFE00-B4CD-482A-9AF6-EF9C792B7D3FQ38981397-DFDABCBE-0304-4C1E-A4DA-7E6DC1C1DA4BQ39147849-CE09A8B4-7E71-41B5-BA83-0EED6B9E93A3Q39577254-8CC52837-D5F1-44F1-8660-4A95E0756589Q39594331-716EE5B2-A039-423D-BC4A-F2DACBF321CAQ39879703-2F1BD7A7-F0BE-4701-A478-1B80FF263C91Q40212000-8DB6AB31-313A-4455-84A9-CD6116166DB7Q40281991-0BFC6012-64C4-46EB-9EA4-7321ABA53E51Q40303951-5B2B8392-3D5E-4301-BAA5-5C3BEA5DD624Q40315393-E606A34C-A966-4925-88C2-9F6203DA4524Q40325166-6C598EAC-66D7-4E06-A324-7270946E27D5Q40350783-46245241-0E42-4376-8B9A-23A99EFBAAEDQ40352823-E49A5F01-5C94-4794-9825-73D44E346193Q40375783-55E9CC66-9DDA-4D68-BE1F-D9C354ED99E1Q40415476-9F615D18-F93D-4A56-8092-76FB19051CAAQ40424918-3DDFFA8A-9B14-4FFE-BFD9-F7452FA0BBD0Q40573594-5B35FEE3-0D46-4AD4-8218-FD6D9F892D2BQ40635231-CB57F730-3CC5-46B5-8164-5496964749F3
P2860
Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Background and rationale for r ...... Cephalosporins and Aztreonam.
@en
type
label
Background and rationale for r ...... Cephalosporins and Aztreonam.
@en
prefLabel
Background and rationale for r ...... Cephalosporins and Aztreonam.
@en
P2093
P2860
P356
P1476
Background and rationale for r ...... Cephalosporins and Aztreonam.
@en
P2093
Antimicrobial Susceptibility T ...... Laboratory Standards Institute
Mary Jane Ferraro
Michael N Dudley
Paul G Ambrose
Ronald N Jones
Sujata M Bhavnani
William A Craig
P2860
P304
P356
10.1093/CID/CIT017
P407
P577
2013-01-18T00:00:00Z